Shares of Novavax dropped by a staggering 12.66% to $206.94 at 11:21 EST on Monday, after three sequential sessions in a row of losses. NASDAQ Composite is falling 0% to $0.00, following the last session’s downward trend, This seems, as yet, a somewhat positive trend trading session today.

Novavax’s last close was $236.93, 60.28% under its 52-week high of $331.68.

News about Novavax today

Novavax begins testing its Covid-19 vaccine candidate in teens. According to today’s article on MarketWatch, "Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax’s experimental vaccine is currently being tested in a late-stage trial that began in December in the U.S. and Mexico. "

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 3072.2%, now sitting on 475.6M for the twelve trailing months.

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $206.94 at 11:21 EST, way under its 52-week high of $331.68 and way higher than its 52-week low of $14.38.

Novavax’s Moving Average

Novavax’s worth is under its 50-day moving average of $210.81 and way above its 200-day moving average of $149.03.

More news about Novavax.

LEAVE A REPLY

Please enter your comment!
Please enter your name here